Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Additional TRK Tumor Types and Molecular Diagnostics

Intended Audience: Oncologists, Pathologists, Surgeons, Community HCPs, Patients/Caregivers

Areas of interest based on referenced literature:

• Role of NTRK gene fusion and impact of TRK-fusion testing in treatment algorithms
• Implication of TRK pathway aberrations in the pathogenesis of cancer
• Education on biomarker driven testing strategies/appropriate testing modalities
• Multi-disciplinary approach to precision medicine
• Understanding of efficacy and safety profiles of approved TRK inhibitors
• Current and future methods to detect molecular alterations
• Comparison of different diagnostic approaches

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget

Provider Justification:

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic areas

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

Diagnosis, treatment and management of TRK fusion cancer

1. Hong DS, Bauer TM, Lee JJ et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1;30(2):325-331. (link)
2. Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family protein in cancer. Pharmacol Ther 2017 (173), 58-66. (link)
3. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
4. Cocco, E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (link)
5. Albert, CM et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. J Clin Oncol. 2019 Feb 20;37(6):513-524. (link)
6. Hyman, DM et al. Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer. Annals of Oncology 30 (5), October 2019 (link)
7. Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (link)
8. Cocco, E et al. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Res. 2019 Mar 15;79(6):1047-1053. (link)
9. Ricciuti, B et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019 Apr 30;12:3171-3179 (link)
10. Solomon, JP et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019 Aug 2. (Epub ahead of print) (link)
11. Wong, D et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019 Jun 29. (Epub ahead of print) (link)
12. van Tilburg, CM et al. Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients. Journal of Clinical Oncology 37, 2019 (suppl; abstr 10010) (link)
13. Hong, D et al. Long-term efficacy and safety of larotrectinib in an integrated database of patients with TRK fusion cancer. ASCO 2021 presentation.
14. Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021 Sep 17;5(1):86. doi: 10.1038/s41698-021-00222-y. https://pubmed.ncbi.nlm.nih.gov/34535754/